Cargando…

MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?

Gastric cancer remains a disease with a dismal prognosis. Extensive efforts to find targetable disease drivers in gastric cancer were implemented to improve patient outcomes. Beyond anti-HER2 therapy, MET pathway seems to be culprit of cancer invasiveness with MET-overexpressing tumors having poorer...

Descripción completa

Detalles Bibliográficos
Autores principales:	El Darsa, Haidar, El Sayed, Rola, Abdel-Rahman, Omar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7547764/ https://www.ncbi.nlm.nih.gov/pubmed/33116950 http://dx.doi.org/10.2147/JEP.S242958

Ejemplares similares

Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
por: ElHalawani, Hesham, et al.
Publicado: (2015)

Ascorbic Acid in Colon Cancer: From the Basic to the Clinical Applications
por: El Halabi, Ibrahim, et al.
Publicado: (2018)

Successful treatment of severe aplastic anemia with syngeneic stem cell transplantation in the setting of active disseminated mucormycosis
por: El-Cheikh, Jean, et al.
Publicado: (2019)

Isothiocyanatostilbenes as novel c-Met inhibitors
por: Gray, Alana L., et al.
Publicado: (2015)

The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment
por: Parikh, Rahul A, et al.
Publicado: (2014)

Metabolic Factors Affecting Tumor Immunogenicity: What Is Happening at the Cellular Level?
por: El Sayed, Rola, et al.
Publicado: (2021)

Anxiety, Depression and Quality of Life in Breast Cancer Patients in the Levant
por: Akel, Reem, et al.
Publicado: (2017)

Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
por: Frigault, Melanie M., et al.
Publicado: (2020)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Immunotherapy in Extensive-Stage Small Cell Lung Cancer
por: El Sayed, Rola, et al.
Publicado: (2021)

The Significance of MET Expression and Strategies of Targeting MET Treatment in Advanced Gastric Cancer
por: Liao, Haiyan, et al.
Publicado: (2021)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis
por: Abdel-Rahman, Omar, et al.
Publicado: (2015)

Targeting autophagy potentiates antitumor activity of Met-TKIs against Met-amplified gastric cancer
por: Lin, Xiaoting, et al.
Publicado: (2019)

MET amplification as a potential therapeutic target in gastric cancer
por: Kawakami, Hisato, et al.
Publicado: (2012)

The Role of cMET in Gastric Cancer—A Review of the Literature
por: Van Herpe, Filip, et al.
Publicado: (2023)

Overexpression of FGFR2 contributes to inherent resistance to MET inhibitors in MET-amplified patient-derived gastric cancer xenografts
por: LIU, KAI, et al.
Publicado: (2015)

(−)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer
por: Siddique, Abu Bakar, et al.
Publicado: (2020)

Endocrine and Targeted Therapy for Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer: Insights to Sequencing Treatment and Overcoming Resistance Based on Clinical Trials
por: El Sayed, Rola, et al.
Publicado: (2019)

The oleocanthal-based homovanillyl sinapate as a novel c-Met inhibitor
por: Mohyeldin, Mohamed M., et al.
Publicado: (2016)

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
por: De Mello, Ramon Andrade, et al.
Publicado: (2020)

Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors
por: Ohm, Hyejee, et al.
Publicado: (2023)

Inhibition of c‐MET increases the antitumour activity of PARP inhibitors in gastric cancer models
por: Koustas, Evangelos, et al.
Publicado: (2020)

Research fellowship in a Lebanese academic medical center: What does it take to shift from an informal to a formal program?
por: Chakhtoura, Marlene, et al.
Publicado: (2022)

Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors
por: Smyth, Elizabeth C, et al.
Publicado: (2014)

Development of antibody-based c-Met inhibitors for targeted cancer therapy
por: Lee, Dongheon, et al.
Publicado: (2015)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside
por: Hardy-Werbin, Max, et al.
Publicado: (2019)

A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma
por: Yashiro, M, et al.
Publicado: (2013)

Resistance to the c-Met inhibitor KRC-108 induces the epithelial transition of gastric cancer cells
por: KIM, DONG CHUL, et al.
Publicado: (2016)

Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review
por: Haibe, Yolla, et al.
Publicado: (2020)

ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors
por: Escorcia, Freddy E., et al.
Publicado: (2020)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
por: Albers, Joachim, et al.
Publicado: (2023)

c-Met inhibitors
por: Mughal, Anum, et al.
Publicado: (2013)

Managing 5FU Cardiotoxicity in Colorectal Cancer Treatment
por: Anaka, Matthew, et al.
Publicado: (2022)

Progress of antibody-based inhibitors of the HGF–cMET axis in cancer therapy
por: Kim, Ki-Hyun, et al.
Publicado: (2017)

Met in Urological Cancers
por: Miyata, Yasuyoshi, et al.
Publicado: (2014)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer
por: Sun, Dantong, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_k7kagm31dfd72ao4iaktt32f7k